Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Many patients with obsessive-compulsive disorder do not respond adequately to serotonin reuptake inhibitors. Augmentation with antipsychotic drugs can be beneficial in this regard. However, since new relevant randomized controlled trials evaluating new antipsychotics were conducted, a recalculation of the effect sizes appears necessary. We meta-analyzed all double-blind, randomized, placebo-controlled trials comparing augmentation of serotonin reuptake inhibitors with antipsychotics to placebo supplementation in treatment-resistant obsessive-compulsive disorder. The primary outcome was mean change in the Yale-Brown Obsessive–Compulsive Scale total score. Secondary outcomes were obsessions, compulsions, response rates, and attrition rates. The data collection process was conducted independently by 2 authors. Hedges’s g and risks ratios were calculated as effect sizes. In preplanned meta-regressions, subgroup analyses, and sensitivity analyses, we examined the robustness of the results and explored reasons for potential heterogeneity. Altogether, 14 double-blind, randomized, placebo-controlled trials (n=491) investigating quetiapine (N=4, n=142), risperidone (N=4, n=132), aripiprazole (N=2, n=79), olanzapine (N=2, n=70), paliperidone (N=1, n=34), and haloperidol (N=1, n=34) were incorporated. Augmentation with antipsychotics was significantly more efficacious than placebo in Yale-Brown Obsessive–Compulsive Scale total reduction (N=14, n=478; Hedges’s g=-0.64, 95% CI: -0.87 to -0.41; P=<.01). Aripiprazole (Hedges’s g=-1.35), haloperidol (Hedges’s g=-0.82), and risperidone (Hedges’s g=-0.59) significantly outperformed placebo. Antipsychotics were superior to placebo in treating obsessions, compulsions, and achieving response. There was no between-group difference concerning all-cause discontinuation. The nonsignificant meta-regressions suggest no influence of the antipsychotic dose or baseline symptom severity on the meta-analytic results. According to our findings, antipsychotic augmentation of serotonin reuptake inhibitors can be regarded as an evidence-based measure in treatment-resistant obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.](https://figures.cochat.ai/paper-figures/557e47f3e0974917a52a232803937ae6/antipsychotic-augmentation-of-serotonin-reuptake-inhibitors-in-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst dopaminergic medications are not first-line treatments for OCD, dopamine receptor antagonists are often used to augment first-line treatment in refractory cases (Hirschtritt et al. 2017) and the efficacy of this strategy is confirmed by meta-analyses (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
In the citing paper
“meta-analysis confirms that dopamine receptor antagonists reduce obsessive-compulsive symptoms in SSRI-refractory OCD (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“A potential publication bias was examined by funnel-plot visualization and accomplishment of Egger`s regression intercept test (2-tailed) (Egger et al., 1997).”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Haenszel random-effects model of Der-Simonian and Laired (Der-Simonian and Laird, 1986)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“…tic disorder (McDougle et al., 1994, 2000; Shapira et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Fineberg et al., 2005; Kordon et al., 2008; Simpson et al., 2013) did not alter the combined overall effect sizes in terms of statistical significance (N = 6, n = 195; Hedges’s g =…”
BackgroundA Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 1×
“Moreover, we estimated the number of negative unpublished trials (fail-safe N value) that would be necessary to dissolve statistically significant differences (Orwin, 1983).”
BackgroundInternational Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 3×
“In unrestricted maximum-likelihood meta-regression analyses, we investigated the impact of the continuous moderators: (1) mean administered antipsychotic dose (calculated as olanzapine equivalents according to the International Consensus Study of Antipsychotic Dosing [Gardner et al., 2010]); and (2) baseline symptom s…”
MethodInfluentialKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Research works printed but not linked: 2
- Borenstein, 2006, Comprehensive meta-analysis, version 2
- The Cochrane Collaboration, 2014, Review Manager (RevMan) [Computer program]. Version 5.3
Cited by
Items 101–140 of 140
Tourette- und Tic-Störungen in Kindheit und Jugend
Döpfner, M., & Roessner, V. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-49289-5_122-1 · Cited by 1
Bilateral Anterior Capsulotomy for Treatment-Resistant Obsessive-Compulsive Disorder
Hurwitz, T. A., Ching, G., Bogod, N. M., & Honey, C. R. (2024) · Stereotactic and Functional Neurosurgery · doi:10.1159/000540503 · Cited by 2
Psychopharmacology for Pediatric OCD and Related Disorders
Greenberg, E., Johnson, G., & GELLER, D. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_10 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Obsessive-Compulsive and Related Disorders in Older Age
Suo, S., & Chadha, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-67555-8_13 · Cited by 1
Drug Augmentation Strategies for Treatment-Resistant Obsessive-Compulsive and Related Disorders
Shavitt, R. G., & Diniz, J. B. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.019
Antipsychotika der zweiten Generation bei der Behandlung von Zwangserkrankungen
Meyer, M. (2018) · mediaTUM (Technical University of Munich)
Multidimensional Approaches for A Case of Severe Adult Obsessive - Compulsive Disorder.
Shi, Z., Mei, X., Zhu, Y., Shuai, Y., Chen, Y.-P., Wu, Y., & Shen, Y. (2017) · PubMed Central · doi:10.11919/j.issn.1002-0829.217019 · Cited by 1
“Specifically, this systematic review indicated that Aripiprazole was significantly superior to placebo in reducing Y-BOCS total score, as well as treating obsessions and compulsions.([12]) Aripiprazole was regarded as the augmenting drug of first choice, and may have particular merits in such difficult-to-treat OCD ca…”
BackgroundPoppe, C., & Voderholzer, U. (2016) · Elsevier eBooks · doi:10.1016/b978-3-437-23731-7.00019-3
Psychotropic Drug Treatment in Later Life
Davies, S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.020 · Cited by 1
Obsessive-Compulsive Spectrum Disorders in Children and Adolescents
Ramsey, K. A., Myers, N. S., Reagan, S., & Mcguire, J. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00082-0
Optical Activation of GABA Release from D2-Medium Spiny Neurons
Affinnih, N. (2020) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/0v1g-rvg9
Obsessive Compulsive Disorder: Neurobiology and Treatment
Hoffman, K. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00161-4
Management of Patients With Obsessive-Compulsive Disorder: Focus on Pharmacotherapy
Maziero, M. P., Macaya, D., Shavitt, R. G., Diniz, J. B., Miguel, E. C., da Silva, R. D. M. F., & Costa, D. L. D. C. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220315-01
Obsessive‐compulsive disorder and men's health. Part 2: Treatment and related sexual dysfunction
Conti, D., Pellegrini, L., Riaz, M., Mpavaenda, D., Sim, A., & Fineberg, N. A. (2023) · Trends in Urology & Men s Health · doi:10.1002/tre.908
Obsessive-Compulsive and Related Disorders
Chadha, P., & Suo, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-47802-4_13
Obsessive-Compulsive and Related Disorders
Drummond, L. M., Enara, A., Cirnigliaro, G., Burkauskas, J., & Fineberg, N. A. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.017
Osman, H. I. (2024) · International Journal of Research Publications · doi:10.47119/ijrp1001501620246668
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Tourette- und Tic-Störungen in Kindheit und Jugend
Döpfner, M., & Roessner, V. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-66744-6_122
Pagliaccio, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_104-1
Pagliaccio, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_104
Innovative treatment approaches for paediatric obsessive-compulsive disorder
Marazziti, D., Gurrieri, R., Gambini, M., Russomanno, G., Palagini, L., & Mucci, F. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2591073
Focus on mood disorders, obsessive–compulsive disorders, and prisoners' treatments
Serretti, A. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000611
Adegbola, A., Dhir, N., & Ogunjobi, O. (2026) · Cureus · doi:10.7759/cureus.102813
“In a meta-analysis of 14 double-blind randomised control trials (RCT), Dold et al. reported that aripiprazole, haloperidol, and risperidone were significantly more effective than quetiapine, olanzapine, and paliperidone compared to placebo [15].”
Pharmacological treatment of obsessive-compulsive disorder in children and adolescents: An overview
Rajalakshmi, A. K., Pawar, A. K. S., & Baweja, R. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v15.i1.114315
Acute Urinary Retention Following Low‐Dose Risperidone in a Young Woman: A Case Report
Zain, O., Iyoun, M. O., Ebido, J., alsrouji, S. K., & Latifeh, Y. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/9961965
Nagoshi, Y. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70145
“Although the efficacy of antipsychotic augmentation for skin-picking behavior has not been established, meta-analytic evidence has shown its effectiveness in patients with SSRI-resistant OCD [5].”
Pinzi, M., Cuomo, A., Carmellini, P., Libri, C., Rescalli, M. B., Pierini, C., Santangelo, A., Patrizio, B., & Fagiolini, A. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124796
“Meta-analytic evidence indicates that antipsychotic augmentation can produce clinically meaningful symptom reduction in approximately 30–40% of patients with SRI-resistant OCD [22,23].”
Cheung, H. K., & Cheung, N. (2026) · Cureus · doi:10.7759/cureus.111573
“For patients with persistent symptoms, antipsychotic augmentation is commonly used, but response is not guaranteed, and adverse effects can limit long-term use [4,5].”
Hadžić, T., Lulla, A., & Nurmi, E. L. (2026) · Current Developmental Disorders Reports · doi:10.1007/s40474-026-00353-6
“Response rates average 40–60% among SSRI nonresponders [18].”
Memantine Augmentation in Obsessive-Compulsive Disorder: A Systematic Review and Meta-analysis
Lyndon, S., & McNally, D. R. (2026) · CNS Drugs · doi:10.1007/s40263-026-01318-4
“The most established augmentation strategy involves second-generation antipsychotics, which can roughly double response rates compared to placebo [4].”
Cheung, N. (2026) · Cureus · doi:10.7759/cureus.113327
“Current treatments act on important systems and remain essential, especially exposure and response prevention, SSRIs, and selected augmentation strategies [1,2].”
Neurochemistry and neurotransmitters involved in obsessive–compulsive disorder
Grant, J. E., & Sohl, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00004-2
Antipsychotics in Anxiety Disorders and Obsessive-compulsive Disorder in Children and Adolescents
Rajalakshmi, A. K., & Greenberg, E. (2026) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2026.07.005
Trastorno obsesivo compulsivo: Naturaleza, evaluación y tratamiento (2017)
López, A. B. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Elnoor, M., Bokhari, S. A., & Javaid, S. F. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12090
Obsessive-compulsive disorder in adulthood: Etiology, diagnosis, and treatment
Voderholzer, U., Jelinek, L., Schennach, R., Domschke, K., Grabe, H. J., & Endres, D. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0156
Pickenhan, L. (2026) · Apollo (University of Cambridge) · doi:10.17863/cam.135532
Metadata
- Authors
- Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S.
- Affiliations
- Universitätsklinikum Tulln (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-04
- Volume
- 18
- Issue
- 9
- Pages
- pyv047
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4576518
- OpenAlex
- W4244844159
- Cited by
- 134
- References
- 49
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 16 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 7 · 2015: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- H. Lundbeck A/S
- Cilag
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- treatment-resistant OCD, antipsychotic augmentation, serotonin reuptake inhibitors, quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol, Yale-Brown Obsessive Compulsive Scale, obsessions and compulsions, treatment response, attrition, antipsychotic dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.